Kymera Therapeutics Inc (KYMR)vsRevolution Medicines Inc (RVMD)
KYMR
Kymera Therapeutics Inc
$114.96
-1.74%
HEALTHCARE · Cap: $9.58B
RVMD
Revolution Medicines Inc
$205.11
+0.66%
HEALTHCARE · Cap: $44.44B
Smart Verdict
WallStSmart Research — data-driven comparison
Kymera Therapeutics Inc generates 14051% more annual revenue ($105.00M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -285.3%. KYMR earns a higher WallStSmart Score of 30/100 (F).
KYMR
Avoid30
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+24.1%
Fair Value
$108.47
Current Price
$114.96
$6.49 discount
Intrinsic value data unavailable for RVMD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 466.4% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Weak financial health signals
ROE of -20.5% — below average capital efficiency
Negative free cash flow — burning cash
Trading at 16.9x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : KYMR
The strongest argument for KYMR centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 466.4% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : KYMR
The primary concerns for KYMR are EPS Growth, Piotroski F-Score, Return on Equity.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
KYMR profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.
KYMR carries more volatility with a beta of 1.97 — expect wider price swings.
KYMR is growing revenue faster at 466.4% — sustainability is the question.
KYMR generates stronger free cash flow (-55M), providing more financial flexibility.
Bottom Line
KYMR scores higher overall (30/100 vs 24/100) and 466.4% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kymera Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down disease-causing proteins by harnessing the body's own natural protein breakdown system. The company is headquartered in Watertown, Massachusetts.
Visit Website →Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?